Abstract 9426: Is Aspirin Beneficial for Primary Prevention of Cardiovascular Events in High-Risk Diabetic Patients? -Insights from the JPAD Trial

Sadanori Okada(Hyogo Medical University), Mio Sakuma(Hyogo Medical University), Hirofumi Soejima(Kumamoto Health Science University), Hisao Ogawa(Kumamoto University Hospital), Atsushi Kubo(Meiji University of Integrative Medicine), Hideaki Jinnouchi, Masako Waki(Shizuoka City Hospital), Masafumi Nakayama(Kumamoto University), Yoshihiko Saito(National Archives and Records Administration), Seigo Sugiyama(Diabetes Care Center), Shiro Uemura(Nara Medical University Hospital), Takeshi Morimoto(Hyogo Medical University), Naofumi Doi(Nara Medical University), Yasuhiro Akai(Nara Medical University), Takahiro Kawano
Circulation
November 22, 2011
10.1161/circ.124.suppl_21.a9426
Cited by 0

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|848